Evidence map›Paper›PMID 31967481›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2020

Design, synthesis and

Yi Le, Yiyuan Gan, Yihong Fu, Jiamin Liu, Wen Li, Xue Zou, Zhixu Zhou, Zhenchao Wang, Guiping Ouyang, Longjia Yan

Open access · goldAbstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 79 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Nanoselenium attenuates renal ischemia-reperfusion injury in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Enzymatic synthesis of fluorinated compounds.Applied microbiology and biotechnology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yi LeState Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, State-Local Joint Laboratory for Comprehensive Utilization of Biomass, Center for Research and Development of Fine Chemicals, Guizhou University, Guiyang, China.
Yiyuan GanSchool of Pharmaceutical Sciences, Guizhou University, Guiyang, China.
Yihong FuSchool of Pharmaceutical Sciences, Guizhou University, Guiyang, China.
Jiamin LiuSchool of Pharmaceutical Sciences, Guizhou University, Guiyang, China.
Wen LiSchool of Pharmaceutical Sciences, Guizhou University, Guiyang, China.
Xue ZouClinical Research Center, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Zhixu ZhouSchool of Pharmaceutical Sciences, Guizhou University, Guiyang, China.
Zhenchao WangSchool of Pharmaceutical Sciences, Guizhou University, Guiyang, China.ORCID http://orcid.org/0000-0003-1859-0128
Guiping OuyangState Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, State-Local Joint Laboratory for Comprehensive Utilization of Biomass, Center for Research and Development of Fine Chemicals, Guizhou University, Guiyang, China.
Longjia YanSchool of Pharmaceutical Sciences, Guizhou University, Guiyang, China.
Guizhou University · CNGuiyang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this paper, a series of novel 3-methyl-quinazolinone derivatives was designed, synthesised and evaluated for antitumor activity

Indexed as

Drug DesignA549 CellsAntineoplastic AgentsApoptosisCell CycleCell ProliferationCrystallography, X-RayDose-Response Relationship, DrugDrug Screening Assays, AntitumorErbB ReceptorsHumansModels, MolecularMolecular StructureProtein Kinase InhibitorsQuinazolinonesStructure-Activity RelationshipAntineoplastic AgentsEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsQuinazolinonesantitumorEGFRmolecular dockingQuinazolinonetyrosine kinase inhibitor

Identifiers

PMID31967481
PMCPMC7006757
OpenAlexW3000892248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.